Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC, HLX10, and HLX04 in HCC with PVTT
NCT04947826Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
serplulimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04947826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947826.